These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17662185)

  • 1. [Positron emission tomography with 18F-fluorodeoxyglucose in patients with uterine sarcoma].
    Rebollo Aguirre AC; Ramos Font C; Bellón Guardia ME; Cabello García D; Gallego Peinado M; Rodríguez Fernández A; Llamas Elvira JM
    Rev Esp Med Nucl; 2007; 26(4):189-95. PubMed ID: 17662185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas.
    Murakami M; Tsukada H; Shida M; Watanabe M; Maeda H; Koido S; Hirasawa T; Muramatsu T; Miyamoto T; Nasu S; Yasuda S; Kajiwara H; Yasuda M; Ide M
    Int J Gynecol Cancer; 2006; 16(2):854-60. PubMed ID: 16681773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging.
    Umesaki N; Tanaka T; Miyama M; Kawamura N; Ogita S; Kawabe J; Okamura T; Koyama K; Ochi H
    Gynecol Oncol; 2001 Mar; 80(3):372-7. PubMed ID: 11263934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
    Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A
    Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: systematic review and meta-analysis of the literature.
    Sadeghi R; Zakavi SR; Hasanzadeh M; Treglia G; Giovanella L; Kadkhodayan S
    Int J Gynecol Cancer; 2013 Oct; 23(8):1349-56. PubMed ID: 23945203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas.
    Bélissant O; Champion L; Thevenet H; Weinmann P; Alberini JL
    Nucl Med Commun; 2018 Jul; 39(7):652-658. PubMed ID: 29683931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.
    Sung PL; Chen YJ; Liu RS; Shieh HJ; Wang PH; Yen MS; Wen KC; Shen SH; Lai CR; Yuan CC
    Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of preoperative ¹⁸F-FDG PET/CT in uterine leiomyosarcoma.
    Park JY; Lee JW; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
    J Gynecol Oncol; 2017 May; 28(3):e28. PubMed ID: 28382795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas.
    Kao YH; Saad U; Tan AE; Magsombol BM; Padhy AK
    Acta Radiol; 2011 May; 52(4):463-6. PubMed ID: 21498277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma.
    Yamamoto M; Tsujikawa T; Yamada S; Kurokawa T; Shinagawa A; Chino Y; Mori T; Kiyono Y; Okazawa H; Yoshida Y
    Oncotarget; 2017 Apr; 8(14):22581-22589. PubMed ID: 28186981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma.
    Ho KC; Lai CH; Wu TI; Ng KK; Yen TC; Lin G; Chang TC; Wang CC; Hsueh S; Huang HJ
    Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):484-92. PubMed ID: 17952435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of
    Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of positron emission tomography (PET) with (18F)fluorodeoxyglucose (FDG) in head and neck tumours.
    Ekberg T; Sörensen J; Engström M; Blomquist E; Sundin A; Anniko M
    Acta Otolaryngol; 2007 Feb; 127(2):186-93. PubMed ID: 17364351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.